PD-1/PD-L1 Inhibitor

PD-1/PD-L1 Inhibitors (194):

Cat. No.	Product Name	Effect	Purity

HY-P9904

Atezolizumab	Inhibitor	98.98%
Atezolizumab (MPDL3280A) is a selective humanized monoclonal IgG1 antibody against programmed death ligand 1 (PD-L1), used for cancer research.

HY-P9902

Pembrolizumab	Inhibitor	99.06%
Pembrolizumab (MK-3475) is a humanized IgG4 antibody inhibiting the programmed cell death 1 (PD-1) receptor, used in cancer immunotherapy.

HY-P99144

Anti-Mouse PD-1 Antibody (RMP1-14)	Inhibitor
Anti-Mouse PD-1 Antibody is an anti-mouse PD-1 IgG2a antibody inhibitor.

HY-16141

Cilengitide	Inhibitor	99.80%
Cilengitide (EMD 121974) is a potent integrins antagonist with IC₅₀s of 0.61 nM (α_νβ₃), 8.4 nM (α_νβ₅) and 14.9 nM (α₅β₁), respectively. Cilengitide inhibits the binding of α_νβ₃ and α_νβ₅ to Vitronectin with IC₅₀s of 4 nM and 79 nM, respectively. Cilengitide inhibits TGF-β/Smad signaling, mediates PD-L1 expression. Cilengitide also induces apoptosis, shows antiangiogenic effect in the research against glioblastoma and other cancers.

HY-P9903

Nivolumab	Inhibitor	99.63%
Nivolumab is a programmed death receptor-1 (PD-1) blocking human IgG4 antibody to treat advanced (metastatic) non-small cell lung cancer.

HY-P9919A

Durvalumab (anti-PD-L1)	Inhibitor	99.90%
Durvalumab (anti-PD-L1)(MEDI 4736) is a human anti-PD-L1 protein monoclonal antibody. Durvalumab (anti-PD-L1) completely blocks PD-L1 binding to PD-1 and CD80, IC₅₀ are 0.1 and 0.04 nM respectively.

HY-P99144A

Anti-Mouse PD-1 Antibody (S-5001)	Inhibitor
Anti-Mouse PD-1 Antibody (S-5001) is an anti-mouse PD-1 IgG1 antibody inhibitor.

HY-P10375

BMS-986189	Inhibitor
BMS-986189 is a macrocyclic peptide inhibitor of PD-L1 (IC₅₀: 1.03 nM), and can be used for cancer research.

HY-P99145

Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2)	Inhibitor	99.60%
Anti-Mouse PD-L1/B7-H1 Antibody is an anti-mouse PD-L1.html" class="link-product" target="_blank">PD-L1 IgG2b antibody inhibitor derived from host rat.

HY-19991

BMS-1	Inhibitor	99.56%
BMS-1 is an inhibitor of the PD-1/PD-L1 protein/protein interaction (IC₅₀ between 6 and 100 nM).

HY-19745

BMS-202	Inhibitor	99.39%
BMS-202 is a potent and nonpeptidic PD-1/PD-L1 complex inhibitor with an IC₅₀ of 18 nM and a K_D of 8 μM. BMS-202 binds to PD-L1 and blocks human PD-1/PD-L1 interaction. BMS-202 has antitumor activity.

HY-P9919

Durvalumab	Inhibitor	99.60%
Durvalumab (MEDI 4736) is an human anti-PD-L1 monoclonal antibody. Durvalumab (MEDI4736) completely blocks the binding of PD-L1 to both PD-1 and CD80, with IC₅₀s of 0.1 and 0.04 nM, respectively.

HY-100022

Tomivosertib	Inhibitor	99.92%
Tomivosertib (eFT508) is a potent, highly selective, and orally active MNK1 and MNK2 inhibitor, with IC₅₀s of 1-2 nM against both isoforms. Tomivosertib (eFT508) treatment leads to a dose-dependent reduction in eIF4E phosphorylation at serine 209 (IC₅₀=2-16 nM) in tumor cell lines. Tomivosertib (eFT508) also dramatically downregulates PD-L1 protein abundance.

HY-78695

JQ-1 (carboxylic acid)	Inhibitor	99.82%
JQ-1 carboxylic acid, a (+)-JQ-1 (HY-13030) derivative, is a potent BET bromodomain inhibitor. JQ-1 carboxylic acid can be used to synthesize PROTAC, which can target the degradation of BRD4.

HY-108730

Avelumab	Inhibitor	99.30%
Avelumab is a fully human IgG1 anti-PD-L1 monoclonal antibody with potential antibody-dependent cell-mediated cytotoxicity.

HY-P9902A

Pembrolizumab (anti-PD-1)	Inhibitor	99.90%
Pembrolizumab (anti-PD-1) is a humanized IgG4 antibody and PD-1 inhibitor. Pembrolizumab produces PD-1 blockade, preventing PD-L1 and PD-L2 from connecting to PD-1. This avoids the uncontrolled regulation of T cells on cells that normally express PD-1.

HY-P99052

Tislelizumab	Inhibitor	98.10%
Tislelizumab, a monoclonal antibody with high binding affinity to the PD-1 receptor, minimizes Fcγ receptor binding on macrophages, thereby abrogating antibody-dependent phagocytosis, a mechanism of T cell clearance and potential resistance to anti-PD-1 research. Tislelizumab can be used for the research of advanced squamous non-small-cell lung cancer.

HY-P9993

Peresolimab	Inhibitor	99.62%
Peresolimab is a humanized IgG1-κ antibody targeting to PD-1. Peresolimab potentially stimulates physiological immune inhibitory pathways to restore immune homeostasis.

HY-P9971

Camrelizumab	Inhibitor	98.80%
Camrelizumab (SHR-1210) is a potent humanied high-affinity IgG4-κ monoclonal antibody (mAb) to PD-1. Camrelizumab binds PD-1 at a high affinity of 3 nM and inhibits the binding interaction of PD-1 and PD-L1 with an IC₅₀ of 0.70 nM. Camrelizumab acts as anti-PD-1/PD-L1 agent and can be used for cancer research, including NSCLC, ESCC, Hodgkin lymphoma, and advanced HCC et,al.

HY-P9997

Rosnilimab	Inhibitor	99.19%
Rosnilimab is a humanized IgG1-κ antibody targeting to PD-1.

Name
Email *

	Sorry, but the email address you supplied was invalid.